UPDATE: Garmin (GRMN) to replace RR Donnelly in S&P 500
Tweet
Share
E-mailGet Alerts GRMN Hot Sheet
Price: $276.04 +0.32%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 7.2%
Revenue Growth %: +12.4%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 7.2%
Revenue Growth %: +12.4%
Join SI Premium – FREE
(Updated - December 5, 2012 5:22 PM EST)
Garmin (NASDAQ: GRMN) to replace RR Donnelley (NASDAQ: RRD) in S&P 500 and RR Donnelley will replace Medicis Pharmaceutical Corp. (NYSE: MRX) in the S&P MidCap 400 after the close of trading Tuesday, December 11.
Valeant Pharmaceuticals International Inc. (NYSE:VRX) is acquiring Medicis.
Garmin (NASDAQ: GRMN) to replace RR Donnelley (NASDAQ: RRD) in S&P 500 and RR Donnelley will replace Medicis Pharmaceutical Corp. (NYSE: MRX) in the S&P MidCap 400 after the close of trading Tuesday, December 11.
Valeant Pharmaceuticals International Inc. (NYSE:VRX) is acquiring Medicis.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- salesforce.com (CRM) Reiterated at Market Outperform by Citizens
- Global S&P Futures mixed to lower in premarket
- SailPoint Technologies Holdings (SAIL) PT Raised to $25 by Cantor Fitzgerald on Solid Checks
Create E-mail Alert Related Categories
Trader TalkRelated Entities
Standard & Poor'sSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
